読み込み中
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
前日終値
$18.39
−$0.11 · -0.59%
日中の時刻はETです。市場データは遅延する場合があります。
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
日中レンジ
現在 $18.39
52週レンジ
現在 $18.39
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
17
著しい割高
センチメント
68
強気
リスク
70
高リスク
モメンタム
47
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
日中レンジ
現在 $18.39
52週レンジ
現在 $18.39
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1000万 USD | 1058.8万 USD | 808.3万 USD | 861.2万 USD | 363.7万 USD |
| 売上原価 | 202.9万 USD | 206万 USD | 195.5万 USD | 84.1万 USD | 2623.7万 USD |
| 粗利益 | 797.1万 USD | 852.8万 USD | 612.8万 USD | 777.1万 USD | −2260万 USD |
| 研究開発 | 1.26億 USD | 6838.8万 USD | 5492.2万 USD | 5344.1万 USD | 2623.7万 USD |
| 販売・一般管理 | 4177.1万 USD | 4104.7万 USD | 2614万 USD | 2226.2万 USD | 1032.9万 USD |
| 営業費用 | 1.66億 USD | 1.07億 USD | 7910.7万 USD | 7486.2万 USD | 1032.9万 USD |
| 受取利息 | 4404.2万 USD | 2985.3万 USD | 1468.6万 USD | 403.2万 USD | 25.7万 USD |
| 減価償却費と償却費 | 202.9万 USD | 206万 USD | 195.5万 USD | 84.1万 USD | 11.3万 USD |
| 営業利益 | −1.58億 USD | −9884.7万 USD | −7297.9万 USD | −6709.1万 USD | −3292.9万 USD |
| 純利益 | −1.14億 USD | −6899.4万 USD | −5829.3万 USD | −6305.9万 USD | −3267.2万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$28.25
上昇余地（53.62%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM2308.66万0.03%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI2302.71万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI2126.95万0.22%98.74億 USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF1034.9万0.01%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB830.16万0.08%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA492.36万0.02%218.24億 USD0.03%$32.79+0.40%
Vanguard Russell 2000 ETFVTWO452.65万0.02%180億 USD0.06%$112.66+0.50%
Federated Hermes MDT Small Cap Core ETFFSCC440.69万1.04%4.24億 USD0.50%$34.00+0.53%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOFederated Hermes MDT Small Cap Core ETFFSCCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
